![]()
|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 43, 40127-40132, October 26, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Natural Sciences, Södertörns
högskola, Box 4101, S-14104 Huddinge, Sweden and the Centers for
Received for publication, April 27, 2001, and in revised form, July 24, 2001
The product of the proto-oncogene
c-myc influences many cellular processes through the
regulation of specific target genes. Through its transactivation domain
(TAD), c-Myc protein interacts with several transcription factors,
including TATA-binding protein (TBP). We present data that suggest that
in contrast to some other transcriptional activators, an extended
length of the c-Myc TAD is required for its binding to TBP. Our data
also show that this interaction is a multistep process, in which a
rapidly forming low affinity complex slowly converts to a more stable
form. The initial complex formation results from ionic or polar
interactions, whereas the slow conversion to a more stable form is
hydrophobic in nature. Based on our results, we suggest two alternative
models for activation domain/target protein interactions, which
together provide a single universal paradigm for understanding
activator-target factor interactions.
c-Myc protein, the product of the proto-oncogene c-myc,
is an important regulator of cell proliferation and apoptosis (Ref. 1
and references therein). These functions are mediated in part by its
activity as a transcriptional activator. Through its C-terminal basic
helix-loop-helix/leucine zipper domain, c-Myc can heterodimerize
with Max (2-4). The Myc/Max heterodimer binds to the
E-box sequence CACGTG and is believed to regulate genes important for
cell cycle progression, including ornithin decarboxylase, Cdc25, cyclin
D, and cul1 (Refs. 5-10 and reviewed in Ref. 11). The transactivation
domain (TAD)1 of c-Myc has
been mapped to the N-terminal 143 amino acids of the protein (12). This
region of the protein includes the "Myc boxes," sequences that are
conserved among members of the Myc protein family and that have been
implicated in Myc's transforming activity. One or both Myc boxes have
also been implicated in the rapid turnover of the c-Myc protein
(13-15) as well as c-Myc's transrepression function (16, 17). The
isolated c-Myc TAD is mostly unstructured in solution (18), a property
it shares with many other activation domains (19-25). Interaction with
target factor induces secondary structure (18), which has been shown to
be important for the function of some transactivators (26-28).
Transcriptional activators act by recruiting other transcription
factors to target genes through protein interactions (29-33). They can
act at multiple steps during transcription, such as regulation of
chromatin accessibility (34-36), preinitiation complex (PIC) formation
(32, 37-40), or post-initiation steps (41, 42). Thus, the formation of
interactions between activators and target proteins is critical for the
regulation of all cellular genes. Despite extensive investigations, the
molecular basis of activation domain function is still poorly
understood, and thus activation domains are still classified according
to their amino acid composition as acidic, glutamine-rich, or
proline-rich. One of the reasons for slow progress may be that many
existing observations appear intrinsically paradoxical. For example,
mutagenesis studies of several highly acidic activation domains have
revealed a predominant importance of hydrophobic amino acids (43-47).
Furthermore, although transactivation domains apparently need to make
specific interactions with several different target factors, they are
usually composed of short amino acid segments with a poor intrinsic
propensity for structure formation (21, 25, 48). Indeed, fortuitous activation domains have even been found within proteins that are not
involved in transcription (49). Early models suggested that the
unstructured acidic activation domains ("acid blobs") recruited components of the transcriptional machinery via nonspecific ionic interactions (50). These models, however, do not account for the
important role of hydrophobic residues, and more recently it has been
shown that some activation domains are structured when bound to target
factors (18, 20, 51, 52).
Here, we characterize the binding of the c-Myc TAD to one of its target
proteins, TBP. We show that TBP needs an extended c-Myc sequence for
interaction. Binding proceeds in two steps, where an initial weak
complex forms rapidly by electrostatic interactions. This weak complex
slowly converts to a more stable form in a reaction that has the
thermodynamic characteristics of protein folding. We present two
alternative models in which single-copy transactivators bind their
target proteins in a stepwise fashion, whereas multicopy transactivators might bind in a simple one-step reaction. Taken together, these results provide a molecular framework for understanding how transcriptional activator proteins can make apparently specific interactions with a large number of different target proteins.
All standard laboratory chemicals were obtained from Sigma or
through Merck Eurolab (Stockholm, Sweden).
Plasmids and Proteins--
Plasmid pT7yD (53) was a kind gift of
Diane Hawley (University of Oregon).
Plasmid pGEXTNBZ was obtained by replacing the
BamHI/SalI fragment of pGEX4T1 (Amersham
Pharmacia Biotech) with a double-stranded oligonucleotide of the
following sequence.
Plasmids pGSTTmyc41 and pGSTT66myc127, encoding the GST fusion
protein of c-Myc amino acids 1-41 and 66-127, respectively, were
constructed by polymerase chain reaction amplification of the
corresponding fragments of c-Myc, including NdeI and
BamHI restriction sites in the amplification primers. The
polymerase chain reaction fragments were ligated into
BamHI/NdeI restricted pGEXTNBZ. These
modifications add six extra amino acids, G-S-P-H-M-A, between the GST
and the Myc part of the fusion protein, as well as two amino acids,
G-S, to the C terminus.
Plasmid pGSTTmyc143 was constructed by cloning the
NdeI/BamHI fragment from pET19myc (18) into
NdeI/BamHI restricted pGEXTNBZ.
The identity of all fusion plasmids was verified by DNA sequencing.
Yeast TBP was overexpressed in Escherichia coli
BL21/DE3(pLysS) transformed with pT7yD and initially purified on
heparin-agarose and DEAE-cellulose as described previously (53)
and further purified on CM-Sepharose (linear gradient 75-400
mM KCl) and phosphocellulose. Purified TBP was dialyzed
into TC100 buffer (20 mM Tris, pH 7.9, 100 mM
KCl, 2 mM EDTA, 10 mM 2-mercaptoethanol, 10%
glycerol) and stored in small aliquots at
GST fusion proteins were overexpressed from the corresponding plasmids
in E. coli BL21/DE3(pLysS). Cells were resuspended in
phosphate-buffered saline supplemented with Complete Protease Inhibitor
(Roche Molecular Biochemicals), lysed by freeze-thawing and sonication,
and the fusion proteins were purified by affinity chromatography on
glutathione-agarose (Sigma) according to standard protocols. GSTmyc143
was further purified and separated from shorter proteolytic products
(mainly free GST) by ion-exchange chromatography on DEAE-Sephacel
(Amersham Pharmacia Biotech), where GST is in the flow-through
fraction, and GSTmyc143 can be eluted from the column with 300 mM KCl. The GST fusion proteins were dialyzed into TC100
and stored in small aliquots at
GST was overexpressed from plasmid pGEXTNBZ, purified on
glutathione-agarose, dialyzed into TC100, and stored at
His-tagged Myc143 was purified as described previously (18).
Protein concentrations were measured with Coomassie Protein Reagent
(Pierce) using bovine serum albumin (Pierce) as a standard, and by UV
absorption. Both techniques gave similar results. All proteins were at
least 95% pure, as judged by SDS-polyacrylamide gel electrophoresis.
Surface Plasmon Resonance (SPR)--
SPR analysis of binding was
performed using a BIAcore2000 instrument under the control of BIAcore
control 3.0 software (BIACORE, Uppsala, Sweden). This setup
allows to simultaneously monitor the binding of one protein dissolved
in the mobile phase to four different proteins immobilized onto
different areas of the sensor chip. Anti-GST antibodies were
immobilized onto all four measuring areas of a Pioneer B1 sensor chip
(both from BIACORE) according to the manufacturer's
instructions, with the flow rate and dual-injection modifications
described by Wu and co-workers (54). For the initial binding
experiments, about 3000 RU of antibody were immobilized. For the
kinetic experiments, areas 1 and 2 were targeted with 500 RU and areas
3 and 4 with 1000 RU of antibody. The binding capacity of the
antibodies was tested by capturing GST protein. Unless otherwise noted,
all binding studies were carried out at 25 °C with HBS-EP (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM
EDTA, 0.005% (v/v) polysorbate 20; BIACORE) supplemented with
10 mM MgCl2 as running buffer.
For kinetic experiments, the measuring areas were regenerated with two
short (1 min) pulses of regeneration buffer (10 mM glycine,
pH 2.2; BIACORE). Subsequently, GST was captured onto areas 1 and 3, and freshly thawed GSTmyc143 was captured onto areas 2 and 4. TBP was thawed on ice, diluted with running buffer to the appropriate
concentration, and injected over all four measuring areas at a flow
rate of 20 µl/min. The recorded data were on-line corrected for
background binding to GST (area 2-area 1, area 4-area 3).
Data analysis was performed with BIAevaluation 3 software
(BIACORE), except for the calculation of rapid equilibrium
constants. Here, Kaleidagraph 3.0 (Abelbeck Software) was used to fit
the binding data to the following equation,
Sensorgrams were simulated using Hopkinsim (Johns Hopkins University),
which is based on the kinsim algorithm (55).
Fluorescence--
Fluorescent analysis of binding was performed
using a Shimadzu RF5000 spectrofluorimeter in a buffer similar in
composition to SPR running buffer, except that it did not contain any
detergent. The slitwidth for both excitation and emission was set to 4 nm. The excitation wavelength was set to 270 nm, and the emission spectrum from 305 to 400 nm was recorded at a scan speed of 0.8 nm/s.
Assuming a 1:1 binding stoichiometry, an equilibrium constant was
estimated using the equation of Swillens (56).
TBP Requires an Extended Myc Sequence for Interaction--
Many
TADs can interact with their target factors via short stretches of
amino acids (54, 57). To find the minimal sequence of c-Myc that
interacts with TBP, we tested shorter fragments of the c-Myc TAD. In a
yeast transactivation assay, two such constructs, residues 1-41 and
66-127, were able to activate transcription, whereas residues 42-65
and 128-149 did not.2 We
therefore prepared GST fusion proteins containing residues 1-41 and
66-127, respectively, as well as the full TAD (1), and tested
them for their ability to interact with TBP, monitoring the interaction
in real time by SPR (Fig. 1). To our
surprise, while TBP interacted efficiently with the full TAD, no
significant interaction with the shorter fragments could be detected.
This suggests that an extended range of residues is needed for
efficient interaction of Myc with TBP and that efficient interaction
requires more than an abundance of acidic residues and/or glutamines
within the TAD.
TBP Interacts with c-Myc in a Biphasic Manner--
When analyzing
the data presented in Fig. 1, we noticed that the interaction appeared
to be biphasic, a very fast initial binding followed by a much slower
increase in response signal. To determine whether the fast phase had
any significance or was an artifact caused by the bulk signal
subtraction (58), we captured different concentrations of GSTmyc143
onto two measuring areas and corresponding amounts of GST onto the
remaining measuring areas. TBP was injected over all four measuring
areas at an increased flow rate to minimize the time delay. The
differential signal GSTmyc143-GST still showed a fast phase (Fig.
2A). Moreover, the magnitude
of the fast phase was proportional to the surface concentration of
GSTmyc143, indicating that it was indeed caused by the interaction between the immobilized Myc protein and TBP. In addition, the wash-out
phase also exhibited a biphasic behavior: a rapid initial drop followed
by a slower reduction. The magnitude of the fast signal loss was
consistently slightly smaller than the fast binding (Fig. 2A
and data not shown).
Such a biphasic response can have several causes. For example,
heterogeneity in the immobilized surface protein, i.e. a
population of GSTmyc143 that binds fast and a population that binds
slowly or a population that binds strongly (slow off-rate) and a
population that binds weakly (fast off-rate) would lead to the observed
behavior. Alternatively, a conformational change in the c-Myc-TBP
complex, transforming it from a fast-dissociating into a
slow-dissociating complex, could also explain the binding data. To
distinguish between these possibilities, we repeatedly injected TBP
over the surface, with the shortest intervening time interval permitted
by the instrument (Fig. 2B). The closer the response
approached saturation, the smaller the relative magnitude of the fast
phase became, both for the binding and the wash-out phases. Such a
behavior is consistent with a conformational change model, but not with
models relying on surface heterogeneity. Importantly, the response
extrapolates to a numeric value consistent with a 1:1 binding stoichiometry.
To be able to estimate rate constants for the reaction, we monitored
the binding of TBP to GSTmyc143 at various TBP concentrations (Fig.
3A). Global analysis using
BIAevaluation, and the pre-defined conformational change model did not
give reliable results, since minor changes in various reaction
parameters caused major changes in the rate constants calculated for
the fast phase. To circumvent this problem, we treated the binding
reaction as a rapid equilibrium followed by a slow conversion
step.
One potential disadvantage of using SPR to monitor binding is that it
is a method in which one reaction partner has to be immobilized close
to a surface. This might change the binding parameters due to steric
hindrance or other problems. While Fig. 2B extrapolates to
the predicted saturation value, indicating that all GSTmyc143
immobilized onto the surface is available for binding, it was still a
formal possibility that the binding characteristics were influenced by
the immobilization. We therefore wanted to monitor the interaction with
an independent method. The fluorescence emission spectrum of TBP
undergoes spectral changes upon binding to DNA (59). A preliminary test
showed that the interaction of TBP with c-Myc also lead to spectral
changes, although of minor magnitude (data not shown). We utilized
these spectral changes to monitor the binding of c-Myc to TBP. A
constant amount of TBP was titrated with small aliquots of His-tagged
c-Myc143, and after waiting for equilibrium, the emission spectra were
recorded. Two mock-titrations were performed, where TBP was titrated
with buffer and where buffer was titrated with c-Myc. The differential
emission between 305 and 315 nm was averaged and plotted
versus the total c-Myc concentration (Fig. 3D).
When analyzed analagous to Swillens (56), an overall apparent
equilibrium constant of 2.3 × 106 liters/mol was
calculated. This corresponds very well with the K0 value calculated from the SPR results, and
thus we conclude that the c-Myc-TBP interaction is not seriously
affected by immobilization of c-Myc to a surface.
The Interaction between c-Myc and TBP Is Entropy-driven--
To
further characterize the interaction between c-Myc and TBP, we
monitored the binding at various temperatures and salt concentrations and analyzed the data as shown in Fig. 3. These and the previous results are summarized in Table I. It is
obvious that the complex is favored at elevated temperatures and that
it is mainly the second step that is affected by temperature (Fig.
4A). The initial binding, the
rapid equilibrium, is not influenced. For the second step, the
conversion from an unstable to a stable complex, van't Hoff analysis,
reveals positive enthalpic and entropic contributions ( The minimal TAD of some activator proteins has been defined as a
very short stretch of continuous amino acids. Examples of such simple
transactivators include the yeast transcriptional activators Gal4p,
where 17 residues are sufficient to activate transcription (54), and
Gln3p, whose minimal transactivation domain has been mapped to 13 residues (57). On the other hand, there are more complex TADs like
those from the mammalian transactivator pax 6 (60) or the human
glucocorticoid receptor (61) for which a larger stretch of amino acid
residues is necessary for efficient transactivation. Our results
indicate that c-Myc is likely to belong to the second class of
transactivators, since an extended activation domain is required for
efficient interaction with TBP (Fig. 1). The interaction with TBP does
not seem to be solely ionic, as has been suggested for some acidic
TADs, since the two shorter fragments that do not interact efficiently
have a net acidity that is higher than the intact TAD. The apparent
contradiction with the finding that the shorter Myc fragments interact
poorly if at all with TBP, yet can nonetheless activate transcription in yeast cells,2 may be reconciled if the relative
intracellular protein concentration is taken into account. The short
fragments were present in concentrations that were orders of magnitude
above the concentration of the construct carrying the full c-Myc TAD
due to the lack of protein degradation signals that are present in the
latter protein (13). This overexpression is likely to lead to increased
occupancy of the c-Myc DNA binding sites in the reporter construct and
thereby to a reduced dependence on high affinity interactions with at
least some target proteins. Thus the findings presented here together
with unpublished work2 strongly suggest that at least two
distinct regions within the c-Myc activation domain contribute to
efficient target factor interaction.
Generally, TADs have little, if any, secondary or tertiary structure
when they are isolated in solution (19-25). However, a small number of
complexes between TADs and their target factors have been studied at
atomic resolution, and all show that the TAD has a distinct tertiary
structure in the complex (20, 52, 62). In many other cases, including
c-Myc, the adoption of secondary structure has been suggested based on
spectral changes or mutational studies (18, 21, 51, 63, 64). The
question that has been unresolved so far is, when this postulated
folding of the TAD takes place. Our results (Figs. 3 and 4) suggest
that initial binding precedes the folding of the TAD. According to the
model shown in Fig. 5A, the
initial contact with target proteins occurs by electrostatic
interactions, presumably between acidic residues of the TAD and
positive charges on the target. This unstable complex has a
dissociation constant in the supermicromolar range. It slowly converts
to a more stable form in a process that involves folding of the TAD
into a defined structure and presumably formation of specific contacts
between the TAD and its target. Supporting evidence for this model
comes from mutational analysis of the VP16 and glucocorticoid receptor
( TADs frequently interact with more than one target factor. A strategy
where the TAD does not fold into a specific structure until it
encounters a target factor can be thermodynamically advantageous. The
intermolecular protein-protein interaction surface can then be fitted
closely to many structurally diverse target proteins, unrestricted by a
pre-formed structure, thus increasing the stability of the complexes
(67). A "bind then fold" strategy can also be advantageous
kinetically, utilizing a postulated pathway that Shoemaker and
co-workers (68) have termed the "flycasting mechanism. " According
to this model an unstructured protein has a larger interaction radius
and thus encounters its target faster than a fully folded protein. The
target can subsequently be "reeled in" through protein folding.
It may be that not all TADs rely on the mechanism proposed in Fig.
5A, despite its potential thermodynamic, kinetic, and
specificity advantages. When an activator binds in multiple copies to
its target genes, as is often the case with artificial reporter gene systems, multiple weak interactions could be sufficient to stabilize the complex and thus achieve transactivation (Fig. 5B). In
such cases folding of the TAD into a specific three-dimensional
structure might not be required. This mechanism might be
physiologically relevant in enhancers of metazoan promoters, where many
transactivators often bind adjacently. Transactivators working through
this latter mechanism of multiple weak interactions might have a
kinetic advantage, since they might be able to bind target proteins
faster than transactivators relying on the bind then fold
mechanism. However, they would lose the specificity achieved by
specific hydrophobic interactions. On naturally occurring promoters, a
"healthy" mixture of fast (but not very specific) and slow (but
specific) activator-target interactions may contribute to the
appropriate balance required for regulated gene expression.
We are grateful to Diane Hawley
(University of Oregon) for providing us with plasmid pT7yD. We thank
Anette Wärnmark and Elizabeth Flinn for interesting
discussions and critical reading of this manuscript.
*
This work was supported by a grant from the Swedish Natural
Science Research Council and by the Swedish Cancer Society.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed. Tel.: 46-8-585-88717;
Fax: 46-8-585-88510; E-mail: Stefan.Hermann@sh.se.
Published, JBC Papers in Press, August 20, 2001, DOI 10.1074/jbc.M103793200
2
E. Flinn and A. P. Wright, manuscript in preparation.
The abbreviations used are:
TAD, transactivation
domain;
TBP, TATA-binding protein;
GST, glutathione
S-transferase;
SPR, surface plasmon resonance;
RU, resonance
units.
How Transcriptional Activators Bind Target Proteins*
§,
Biotechnology and ¶ Structural Biochemistry,
Department of Biosciences, Karolinska Institutet, NOVUM, S-14157
Huddinge, Sweden
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
80 °C.
80 °C.
80 °C.
where
(Eq. 1)
is the fractional saturation and [Tt] is
the total concentration of TBP.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (20K):
[in a new window]
Fig. 1.
A large portion of c-Myc is needed to bind to
TBP. A, schematics of the protein constructs used. The
shaded areas denote protein destruction sequences.
B, about 2000 RU of anti-GST antibody were immobilized onto
all four measuring areas of sensor chip B1. Equal molar amounts of GST,
GSTmyc41, GSTmyc66-127, and GSTmyc143 were captured onto areas 1 to 4, respectively. 1.35 µM TBP was injected over all four
measuring areas at a flow rate of 5 µl/min. Shown here are the
differential responses to area 2-area 1 (GSTmyc41, dashed
line), area 3-area 1 (GSTmyc66-127, dotted line), and
area 4-area 1 (GSTmyc143, solid line).

View larger version (19K):
[in a new window]
Fig. 2.
TBP binds to the c-Myc TAD in a multiphasic
manner. A, TBP at a concentration of 1.3 µM
was injected over all four measuring areas of a sensor chip that had 94 RU, respectively, 205 RU of GSTmyc143 on areas 2 and 4, and
corresponding molar amounts of GST on areas 1 and 3. The sensorgrams
shown here represent the differential signals area 2-area 1 (dotted line) and area 4-area 3 (solid line). The
spikes at the start and end of the injection result from this
background correction. B, to prolong contact time between
immobilized Myc protein and soluble TBP, the flow rate was reduced to 2 µl/min, and TBP at a concentration of 1.3 µM was
repeatedly injected over areas 1 and 2 that had 273 RU GST and 376 RU
GSTmyc143, respectively, captured onto them. The sensorgram shows the
differential signal for area 2-area 1.
To estimate an equilibrium constant KA for the
fast phase, we recorded the magnitude of the fast phase, approximated by the response 10 s after injection, as a function of TBP
concentration. Since Fig. 2B showed a 1:1 stoichiometry,
indicating that all the Myc molecules on the surface are available for
binding, the fast phase response could be converted to a fractional
saturation
(Eq. 2)
(Fig. 3B) and an equilibrium constant
calculated according to Equation 1. An off-rate for the slow phase can
be calculated directly from the data using a simple binding model
(d[Cfinal]/dt = k
2 × [Cfinal]). An
estimate for the rate constant of the slow binding phase can be
obtained with the following differential equation.
Finally, K0, the equilibrium constant for
the overall reaction, can be calculated from the equilibrium constant
for the fast step and the kinetic constants for the slow step. The
parameters thus obtained are KA = 1.1 × 105 liters/mol, k
(Eq. 3)
2 = 2.6 × 10
4 s
1, k2 = 4.7 × 10
3 s
1 and
K0 = 1.9 × 106 liters/mol. To
test the validity of this approach, we simulated this model (Equation 2) using the thermodynamic and kinetic constants obtained above (Fig.
3C). The simulated curve correlates very well with the data,
indicating that the model is a close approximation of reality, whereas
a simple one-step Langmuir binding isotherm does not fit the data (Fig.
3C).

View larger version (22K):
[in a new window]
Fig. 3.
The binding can be modeled as a rapid
equilibrium followed by a slow conversion step. A,
several concentrations of TBP were injected over all four measuring
areas. Areas 2 and 4 had different amounts of GSTmyc143 captured, areas
1 and 3 carried the corresponding amounts of GST. Shown here are the
differential signals for area 4-area 3. The response signal was
divided into four separate phases: fast on, slow on, fast off, slow
off. For the slow off phase, a rate constant of 2.6 × 10
4 s
1 was obtained by global analysis. The
fast on and fast off phases were treated as rapid equilibrium, and an
equilibrium constant could be determined (see B). The rate
constant for the slow on phase could be obtained by first calculating
the concentration of rapid equilibrium complex over time and using this
concentration as a parameter for the conversion reaction. The slow
on-rate was thus estimated to be 4.7 × 10
3
s
1. The apparent overall equilibrium constant could be
calculated to be K0 = 1.9 × 106 liters/mol. B, to estimate a binding
constant for this rapid equilibrium, the response 10 s after the
start of the injection was recorded. The expected response at
saturation was calculated from the known amount of GSTmyc143 on the
surface and the ratio of molecular weights. The fractional saturation
was plotted versus the TBP concentration, and a binding
curve was fitted to the data. The equilibrium constant for the fast
phase was estimated to be 1.1 × 105 liters/mol.
C, curve b from A, corresponding to a
TBP concentration of 1.35 µM, was converted to a
fractional saturation
(solid line). The TBP + Myc
C1
C2 mechanism (Equation 2) was modeled using the parameters obtained
above (dotted line). A simple one-step Langmuir binding
isotherm (dashed line) does not fit the data. D,
TBP changes its fluorescent properties when binding to target protein
(data not shown). A constant amount of TBP was titrated with small
aliquots of His-tagged Myc TAD-(1-143). Mock-titrations were performed
for background correction, titrating TBP with buffer and titrating
buffer with c-Myc. The differential emission between 305 and 315 nm was
averaged and plotted versus the concentration of added
HisMyc143. The titration curve was analyzed analogous to Swillens (56),
and the apparent overall equilibrium constant was estimated to be
K0 = 2.3 × 106
liters/mol.
H = 133 kJ/mol,
S = 479 J
mol
1 K
1), indicating that this
entropy-driven reaction involves hydrophobic interactions. In contrast,
the initial binding step is less stable at elevated salt concentration
(Fig. 4B), suggesting that polar and ionic interactions play
a predominant role.
Summary of the measured affinity constants

View larger version (16K):
[in a new window]
Fig. 4.
Binding of TBP to c-Myc is
entropy-driven. A, the binding of TBP to c-Myc was
monitored by SPR at different temperatures. Binding constants were
determined as described in the legend to Fig. 3. The logarithm of the
estimated binding constants for the first step (squares) and
second step (circles) was plotted against the inverse
temperature, and a straight line fitted to the data. The first step,
the rapid equilibrium, has no clear temperature dependence. For the
second, slow, step, van't Hoff analysis revealed an entropy-driven
process, with
H = 133 kJ mol
1, and
S = 479 J mol
1 K
1. The error
bars represent the S.E., averaged over two measurements for the
initial binding, or the S.D. from eight local fit measurements for the
conversion. B, the binding of TBP to c-Myc was monitored at
different salt concentrations. Equilibrium constants were estimated as
described in the legend to Fig. 3 and plotted against the salt
concentration. The rapid equilibrium (squares) shows a clear
trend, with weaker binding at elevated salt concentrations. The slow
step (circles) is less affected by salt. Error
bars are the same as in A.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1) TADs. These studies revealed that individual acidic residues
were of minor importance, but that the total acidity of the protein was
important for activity (46, 65). In contrast, substitutions of
individual hydrophobic amino acids did affect activity (46, 66).
Interestingly, a group of such mutants that altered the activity of the
1 TAD had similar effects on its interactions with a variety of
target proteins (43). This suggests that the mutations affect a common
mechanism such as protein folding that is an essential prerequisite for stable interaction of the TAD with all target proteins (43).

View larger version (17K):
[in a new window]
Fig. 5.
Model for the TAD-target
interaction. A, a single-copy unstructured TAD
binds weakly to its target. Subsequently, the TAD folds into a specific
three-dimensional structure to interact more stably with its target.
B, multicopy TADs utilize multiple weak interactions to bind
their target. Protein folding is not required.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Pelengaris, S.,
Rudolph, B.,
and Littlewood, T.
(2000)
Curr. Opin. Genet. Dev.
10,
100-105[CrossRef][Medline]
[Order article via Infotrieve]
2.
Kato, G. J.,
Lee, W. M.,
Chen, L. L.,
and Dang, C. V.
(1992)
Genes Dev.
6,
81-92 3.
Dang, C. V.,
McGuire, M.,
Buckmire, M.,
and Lee, W. M.
(1989)
Nature
337,
664-666[CrossRef][Medline]
[Order article via Infotrieve]
4.
Dang, C. V.,
van Dam, H.,
Buckmire, M.,
and Lee, W. M.
(1989)
Mol. Cell. Biol.
9,
2477-2486 5.
Wagner, A. J.,
Meyers, C.,
Laimins, L. A.,
and Hay, N.
(1993)
Cell Growth Differ.
4,
879-883[Abstract]
6.
Galaktionov, K.,
Chen, X.,
and Beach, D.
(1996)
Nature
382,
511-517[CrossRef][Medline]
[Order article via Infotrieve]
7.
Philipp, A.,
Schneider, A.,
Vasrik, I.,
Finke, K.,
Xiong, Y.,
Beach, D.,
Alitalo, K.,
and Eilers, M.
(1994)
Mol. Cell. Biol.
14,
4032-4043 8.
Obaya, A. J.,
Mateyak, M. K.,
and Sedivy, J. M.
(1999)
Oncogene
18,
2934-2941[CrossRef][Medline]
[Order article via Infotrieve]
9.
Schmidt, E. V.
(1999)
Oncogene
18,
2988-2996[CrossRef][Medline]
[Order article via Infotrieve]
10.
O'Hagan, R. C.,
Ohh, M.,
David, G.,
de Alboran, I. M.,
Alt, F. W.,
Kaelin, W. G., Jr.,
and DePinho, R. A.
(2000)
Genes Dev.
14,
2185-2191 11.
Sakamuro, D.,
and Prendergast, G. C.
(1999)
Oncogene
18,
2942-2954[CrossRef][Medline]
[Order article via Infotrieve]
12.
Kato, G. J.,
Barrett, J.,
Villa-Garcia, M.,
and Dang, C. V.
(1990)
Mol. Cell. Biol.
10,
5914-5920 13.
Flinn, E. M.,
Busch, C. M.,
and Wright, A. P.
(1998)
Mol. Cell. Biol.
18,
5961-5969 14.
Salghetti, S. E.,
Muratani, M.,
Wijnen, H.,
Futcher, B.,
and Tansey, W. P.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
3118-3123 15.
Salghetti, S. E.,
Kim, S. Y.,
and Tansey, W. P.
(1999)
EMBO J.
18,
717-726[CrossRef][Medline]
[Order article via Infotrieve]
16.
Penn, L. J.,
Brooks, M. W.,
Laufer, E. M.,
Littlewood, T. D.,
Morgenstern, J. P.,
Evan, G. I.,
Lee, W. M.,
and Land, H.
(1990)
Mol. Cell. Biol.
10,
4961-4966 17.
Li, L. H.,
Nerlov, C.,
Prendergast, G.,
MacGregor, D.,
and Ziff, E. B.
(1994)
EMBO J.
13,
4070-4079[Medline]
[Order article via Infotrieve]
18.
McEwan, I. J.,
Dahlman-Wright, K.,
Ford, J.,
and Wright, A. P.
(1996)
Biochemistry
35,
9584-9593[CrossRef][Medline]
[Order article via Infotrieve]
19.
Lee, H.,
Mok, K. H.,
Muhandiram, R.,
Park, K. H.,
Suk, J. E.,
Kim, D. H.,
Chang, J.,
Sung, Y. C.,
Choi, K. Y.,
and Han, K. H.
(2000)
J. Biol. Chem.
275,
29426-29432 20.
Parker, D.,
Jhala, U. S.,
Radhakrishnan, I.,
Yaffe, M. B.,
Reyes, C.,
Shulman, A. I.,
Cantley, L. C.,
Wright, P. E.,
and Montminy, M.
(1998)
Mol. Cell
2,
353-359[CrossRef][Medline]
[Order article via Infotrieve]
21.
Dahlman-Wright, K.,
Baumann, H.,
McEwan, I. J.,
Almlof, T.,
Wright, A. P.,
Gustafsson, J. A.,
and Hard, T.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
1699-1703 22.
Schmitz, M. L.,
dos Santos Silva, M. A.,
Altmann, H.,
Czisch, M.,
Holak, T. A.,
and Baeuerle, P. A.
(1994)
J. Biol. Chem.
269,
25613-25620 23.
Shen, F.,
Triezenberg, S. J.,
Hensley, P.,
Porter, D.,
and Knutson, J. R.
(1996)
J. Biol. Chem.
271,
4819-4826 24.
Gauthier, J. M.,
Dillner, J.,
and Yaniv, M.
(1991)
Nucleic Acids Res.
19,
7073-7079 25.
Campbell, K. M.,
Terrell, A. R.,
Laybourn, P. J.,
and Lumb, K. J.
(2000)
Biochemistry
39,
2708-2713[CrossRef][Medline]
[Order article via Infotrieve]
26.
Hi, R.,
Osada, S.,
Yumoto, N.,
and Osumi, T.
(1999)
J. Biol. Chem.
274,
35152-35158 27.
Wang, D.,
Moriggl, R.,
Stravopodis, D.,
Carpino, N.,
Marine, J. C.,
Teglund, S.,
Feng, J.,
and Ihle, J. N.
(2000)
EMBO J.
19,
392-399[CrossRef][Medline]
[Order article via Infotrieve]
28.
Warnmark, A.,
Gustafsson, J. A.,
and Wright, A. P.
(2000)
J. Biol. Chem.
275,
15014-15018 29.
Barberis, A.,
Pearlberg, J.,
Simkovich, N.,
Farrell, S.,
Reinagel, P.,
Bamdad, C.,
Sigal, G.,
and Ptashne, M.
(1995)
Cell
81,
359-368[CrossRef][Medline]
[Order article via Infotrieve]
30.
Triezenberg, S. J.
(1995)
Curr. Opin. Genet. Dev.
5,
190-196[CrossRef][Medline]
[Order article via Infotrieve]
31.
Gaudreau, L.,
Schmid, A.,
Blaschke, D.,
Ptashne, M.,
and Horz, W.
(1997)
Cell
89,
55-62[CrossRef][Medline]
[Order article via Infotrieve]
32.
Ptashne, M.,
and Gann, A.
(1997)
Nature
386,
569-577[CrossRef][Medline]
[Order article via Infotrieve]
33.
Zaman, Z.,
Ansari, A. Z.,
Gaudreau, L.,
Nevado, J.,
and Ptashne, M.
(1998)
Cold Spring Harbor Symp. Quant. Biol.
63,
167-171[CrossRef][Medline]
[Order article via Infotrieve]
34.
Ait-Si-Ali, S.,
Polesskaya, A.,
Filleur, S.,
Ferreira, R.,
Duquet, A.,
Robin, P.,
Vervish, A.,
Trouche, D.,
Cabon, F.,
and Harel-Bellan, A.
(2000)
Oncogene
19,
2430-2437[CrossRef][Medline]
[Order article via Infotrieve]
35.
Beato, M.,
and Eisfeld, K.
(1997)
Nucleic Acids Res.
25,
3559-3563 36.
Berk, A. J.,
Boyer, T. G.,
Kapanidis, A. N.,
Ebright, R. H.,
Kobayashi, N. N.,
Horn, P. J.,
Sullivan, S. M.,
Koop, R.,
Surby, M. A.,
and Triezenberg, S. J.
(1998)
Cold Spring Harbor Symp. Quant. Biol.
63,
243-252[CrossRef][Medline]
[Order article via Infotrieve]
37.
Farrell, S.,
Simkovich, N.,
Wu, Y.,
Barberis, A.,
and Ptashne, M.
(1996)
Genes Dev.
10,
2359-2367 38.
Gaudreau, L.,
Adam, M.,
and Ptashne, M.
(1998)
Mol. Cell
1,
913-916[CrossRef][Medline]
[Order article via Infotrieve]
39.
Koh, S. S.,
Ansari, A. Z.,
Ptashne, M.,
and Young, R. A.
(1998)
Mol. Cell
1,
895-904[CrossRef][Medline]
[Order article via Infotrieve]
40.
Nevado, J.,
Gaudreau, L.,
Adam, M.,
and Ptashne, M.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
2674-2677 41.
Brown, S. A.,
Weirich, C. S.,
Newton, E. M.,
and Kingston, R. E.
(1998)
EMBO J.
17,
3146-3154[CrossRef][Medline]
[Order article via Infotrieve]
42.
Sune, C.,
and Garcia-Blanco, M. A.
(1999)
Mol. Cell. Biol.
19,
4719-4728 43.
Almlof, T.,
Wallberg, A. E.,
Gustafsson, J. A.,
and Wright, A. P.
(1998)
Biochemistry
37,
9586-9594[CrossRef][Medline]
[Order article via Infotrieve]
44.
Blair, W. S.,
Bogerd, H. P.,
Madore, S. J.,
and Cullen, B. R.
(1994)
Mol. Cell. Biol.
14,
7226-7234 45.
Chang, J.,
Kim, D. H.,
Lee, S. W.,
Choi, K. Y.,
and Sung, Y. C.
(1995)
J. Biol. Chem.
270,
25014-25019 46.
Cress, W. D.,
and Triezenberg, S. J.
(1991)
Science
251,
87-90 47.
Drysdale, C. M.,
Duenas, E.,
Jackson, B. M.,
Reusser, U.,
Braus, G. H.,
and Hinnebusch, A. G.
(1995)
Mol. Cell. Biol.
15,
1220-1233[Abstract]
48.
Botuyan, M. V.,
Momand, J.,
and Chen, Y.
(1997)
Fold Des.
2,
331-342[CrossRef][Medline]
[Order article via Infotrieve]
49.
Ruden, D. M.,
Ma, J.,
Li, Y.,
Wood, K.,
and Ptashne, M.
(1991)
Nature
350,
250-252[CrossRef][Medline]
[Order article via Infotrieve]
50.
Ptashne, M.,
and Gann, A. A.
(1990)
Nature
346,
329-331[CrossRef][Medline]
[Order article via Infotrieve]
51.
Massari, M. E.,
Jennings, P. A.,
and Murre, C.
(1996)
Mol. Cell. Biol.
16,
121-129[Abstract]
52.
Radhakrishnan, I.,
Perez-Alvarado, G. C.,
Parker, D.,
Dyson, H. J.,
Montminy, M. R.,
and Wright, P. E.
(1997)
Cell
91,
741-752[CrossRef][Medline]
[Order article via Infotrieve]
53.
Hoopes, B. C.,
LeBlanc, J. F.,
and Hawley, D. K.
(1992)
J. Biol. Chem.
267,
11539-11547 54.
Wu, Y.,
Reece, R. J.,
and Ptashne, M.
(1996)
EMBO J.
15,
3951-3963[Medline]
[Order article via Infotrieve]
55.
Barshop, B. A.,
Wrenn, R. F.,
and Frieden, C.
(1983)
Anal. Biochem.
130,
134-145[CrossRef][Medline]
[Order article via Infotrieve]
56.
Swillens, S.
(1995)
Mol. Pharmacol.
47,
1197-1203[Abstract]
57.
Svetlov, V.,
and Cooper, T. G.
(1997)
J. Bacteriol.
179,
7644-7652 58.
Ober, R. J.,
and Ward, E. S.
(1999)
Anal. Biochem.
273,
49-59[CrossRef][Medline]
[Order article via Infotrieve]
59.
Perez-Howard, G. M.,
Weil, P. A.,
and Beechem, J. M.
(1995)
Biochemistry
34,
8005-8017[CrossRef][Medline]
[Order article via Infotrieve]
60.
Tang, H. K.,
Singh, S.,
and Saunders, G. F.
(1998)
J. Biol. Chem.
273,
7210-7221 61.
Dahlman-Wright, K.,
Almlof, T.,
McEwan, I. J.,
Gustafsson, J. A.,
and Wright, A. P.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
1619-1623 62.
Uesugi, M.,
Nyanguile, O.,
Lu, H.,
Levine, A. J.,
and Verdine, G. L.
(1997)
Science
277,
1310-1313 63.
Dahlman-Wright, K.,
and McEwan, I. J.
(1996)
Biochemistry
35,
1323-1327[CrossRef][Medline]
[Order article via Infotrieve]
64.
Defossez, P. A.,
Baert, J. L.,
Monnot, M.,
and de Launoit, Y.
(1997)
Nucleic Acids Res.
25,
4455-4463 65.
Almlof, T.,
Wright, A. P.,
and Gustafsson, J. A.
(1995)
J. Biol. Chem.
270,
17535-17540 66.
Almlof, T.,
Gustafsson, J. A.,
and Wright, A. P.
(1997)
Mol. Cell. Biol.
17,
934-945[Abstract]
67.
Tsai, C. J.,
Xu, D.,
and Nussinov, R.
(1997)
Protein Sci.
6,
1793-1805[Abstract]
68.
Shoemaker, B. A.,
Portman, J. J.,
and Wolynes, P. G.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
8868-8873
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
A. Johnsson, Y. Xue-Franzen, M. Lundin, and A. P. H. Wright Stress-specific role of fission yeast gcn5 histone acetyltransferase in programming a subset of stress response genes. Eukaryot. Cell, August 1, 2006; 5(8): 1337 - 1346. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Copik, M. S. Webb, A. L. Miller, Y. Wang, R. Kumar, and E. B. Thompson Activation Function 1 of Glucocorticoid Receptor Binds TATA-Binding Protein in Vitro and in Vivo Mol. Endocrinol., June 1, 2006; 20(6): 1218 - 1230. [Abstract] [Full Text] [PDF] |
||||
![]() |
R A Sporici, J S Hodskins, D M Locasto, L B Meszaros, A L Ferry, A M Weidner, C A Rinehart, J C Bailey, I M Mains, and S E Diamond Repression of the prolactin promoter: a functional consequence of the heterodimerization between Pit-1 and Pit-1 {beta} J. Mol. Endocrinol., October 1, 2005; 35(2): 317 - 331. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Ferreira, S. Hermann, P. Prochasson, J. L. Workman, K. D. Berndt, and A. P. H. Wright Mechanism of Transcription Factor Recruitment by Acidic Activators J. Biol. Chem., June 10, 2005; 280(23): 21779 - 21784. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Friedman, H. Khanna, P. K. Swain, R. DeNicola, H. Cheng, K. P. Mitton, C. H. Weber, D. Hicks, and A. Swaroop The Minimal Transactivation Domain of the Basic Motif-Leucine Zipper Transcription Factor NRL Interacts with TATA-binding Protein J. Biol. Chem., November 5, 2004; 279(45): 47233 - 47241. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Warnmark, E. Treuter, A. P. H. Wright, and J.-A. Gustafsson Activation Functions 1 and 2 of Nuclear Receptors: Molecular Strategies for Transcriptional Activation Mol. Endocrinol., October 1, 2003; 17(10): 1901 - 1909. [Abstract] [Full Text] [PDF] |
||||
![]() |